Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC

Journal of Clinical Oncology

Volumn 13, Issue 6, 1995, Pages 1384-1390

  Sarkis, Alvoro S ^a   Bajorin, Dean F ^a   Reuter, Victor E ^a   Herr, Harry W ^a   Netto, George ^a   Zhang, Zuo Feng ^a   Schultz, Paul K ^a   Cordon Cardo, Carlos ^a   Scher, Howard I ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; METHOTREXATE; PROTEIN P53; VINBLASTINE;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER INVASION; CANCER SURVIVAL; CLINICAL TRIAL; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

EID: 0029063351     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1995.13.6.1384     Document Type: Article

References (37)

1. Perez CA, Fair WR, Ihde DC: Cancer of the bladder, in DeVita VT, Hellman S, Rosenberg SA (eds): Principles and Practice of Oncology, vol 4. Philadelphia, PA, Lippincott, 1993, pp 1052-1072
2. Scher HI, Splinter TA: Neoadjuvant chemotherapy for invasive bladder cancer: Future directions. Semin Oncol 17:635-638, 1990
3. Splinter TA, Scher HI, Denis L, et al: The prognostic value of the pT-category after combination chemotherapy for patients with invasive bladder cancer who underwent cystectomy. EORTC-GU group. Prog Clin Biol Res 353:219-224, 1990
4. Splinter TA, Denis L, Scher HI, et al: Neoadjuvant chemotherapy of invasive bladder cancer. The prognostic value of local tumor response. Prog Clin Biol Res 303:541-547, 1989
5. Splinter TA, Scher HI, Denis L, et al: The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer - Genitourinary Group. J Urol 147:606-608, 1992
6. Schultz P, Herr HW, Zhang ZF, et al: Neoadjuvant chemotherapy for invasive bladder cancer: Prognostic factors for survival of patients treated with M-VAC with 5-year follow-up. J Clin Oncol 12:1394-1401, 1994
7. Kaufman DS, Shipley WU, Griffin PP, et al: Selective bladder preservation by combination treatment of invasive bladder cancer. N Engl J Med 329:1377-1382, 1993
8. Raghavan D, Pearson B, Tynan A, et al: Preemptive (neoadjuvant) chemotherapy for invasive bladder cancer: A decade of experience. Semin Urol 8:285-290, 1990
9. Barak Y, Juven T, Haffner R, et al: mdm2 expression is induced by wild type p53 activity. EMBO J 12:461-468, 1992
10. Dalbagni G, Presti J, Reuter VE, et al: Molecular genetic alterations of chromosome 17 and p53 nuclear overexpression in human bladder cancer. Diagn Mol Pathol 2:4-13, 1993
11. Lipponen PK: Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int J Cancer 53:365-370, 1993
12. Spruck I, Rideout WM, Olumi AF, et al: Distinct pattern of p53 mutations in bladder cancer: Relationship to tobacco usage. Cancer Res 53:1162-1166, 1993
13. Fields S, Jang SK: Presence of a potent transcription activating sequence in the p53 protein. Science 249:1046-1049, 1990
14. Raycroft L, Wu H, Lozano G: Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science 249:1049-1051, 1990
15. Finlay CA, Hinds PW, Levine AJ: The p53 proto-oncogene can act as suppressor of transformation. Cell 57:1083-1093, 1989
16. Hupp TR, Meek DW, Midgley CA, et al: Regulation of the specific DNA binding function of p53. Cell 71:875-886, 1992
17. Yin Y, Tainsky MA, Bischoff FZ, et al: Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70:937-948, 1992
18. Levine AJ, Momand J, Finlay CA: The p53 tumor suppressor gene. Nature 351:453-456, 1991
19. Finlay CA, Hinds PW, Tan TH, et al: Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 8:531-539, 1988
20. Momand J, Zambetti GP, Olson DC, et al: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237-1245, 1992
21. Scheffner M, Werness BA, Huibregtse JM, et al: The E6 oncoprotein encoded by human papilloma virus types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136, 1990
22. Cordon-Cardo C, Dalbagni G, Saez GT, et al: p53 mutations in human bladder cancer: Genotypic versus phenotypic patterns. Int J Cancer 56:347-353, 1994
23. Esrig D, Spruck CH, Nichols PW, et al: p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. J Pathol 143:1390-1397, 1993
24. Sarkis AS, Dalbagni G, Melaned J, et al: Prognostic significance of p53 nuclear overexpression in superficially invasive (T1) bladder carcinoma (TCC). J Urol 149:238A, 1993 (abstr)
25. Sarkis AS, Dalbagni G, Cordon-Cardo C, et al: Nuclear overexpression of p53 protein in transditional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 85:53-59, 1993
26. Sarkis AS, Zhang Z-F, Cordon-Cardo C, et al: p53 nuclear overexpression and disease progression in Ta bladder carcinoma. Int J Oncol 3:355-360, 1993
27. Cordon-Cardo C, Finstad CL, Bander NH, et al: Immunoanatomic distribution of cytostructural and tissue-associated antigens of the human urinary tract. Am J Pathol 126:269-284, 1987
28. Banks L, Matlashewski G, Crawford L: Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 159:529-534, 1986
29. Cordon-Cardo C, Dalbagni G, Saez GT, et al: p53 mutations in human bladder cancer: Genotypic versus phentypic patterns. Int J Cancer 56:347-353-1994, 1995
30. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
31. Cox DR: Partial likelihood. Biometrika 62:269-279, 1975
32. Sarkis AS, Dalbagni G, Cordon-Cardo C, et al: Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol 52:388-392, 1994
33. Cordon-Cardo C, Wartinger D, Petrylak D, et al: Altered expression of the retinoblastoma gene product: Prognostic indicator in bladder cancer. J Natl Cancer Inst 84:1251-1256, 1992
34. Logothetis CJ, Xu H, Ro JY, et al: Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J Natl Cancer Inst 84:1256-1261, 1992
35. Lowe SW, Ruley HE, Jacks T, et al: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967, 1993
36. Splinter T, Denis L: Restaging procedures, criteria of response, and relationship between pathological response and survival. Semin Oncol 17:606-612, 1990
37. Lianes P, Orlow I, Zhang Z-F, et al: Altered patterns of MDM2 and TP53 expression in human bladder cancer. J Natl Cancer Inst 86:1265-1266, 1994